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ABSTRACT The aim of this study was to develop and explore the diagnostic accuracy of a decision tree
derived from a large real-life primary care population.
Data from 9297 primary care patients (45% male, mean age 53±17 years) with suspicion of an
obstructive pulmonary disease was derived from an asthma/chronic obstructive pulmonary disease
(COPD) service where patients were assessed using spirometry, the Asthma Control Questionnaire, the
Clinical COPD Questionnaire, history data and medication use. All patients were diagnosed through the
Internet by a pulmonologist. The Chi-squared Automatic Interaction Detection method was used to build
the decision tree. The tree was externally validated in another real-life primary care population (n=3215).
Our tree correctly diagnosed 79% of the asthma patients, 85% of the COPD patients and 32% of the
asthma–COPD overlap syndrome (ACOS) patients. External validation showed a comparable pattern
(correct: asthma 78%, COPD 83%, ACOS 24%).
Our decision tree is considered to be promising because it was based on real-life primary care patients
with a specialist’s diagnosis. In most patients the diagnosis could be correctly predicted. Predicting ACOS,
however, remained a challenge. The total decision tree can be implemented in computer-assisted
diagnostic systems for individual patients. A simplified version of this tree can be used in daily clinical
practice as a desk tool.
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Introduction
Diagnostic reasoning and clinical decision making is essential in daily clinical practice and depends on the
physician’s ability to synthesise and interpret clinical information. Different attempts have been made to
support physicians in this process by developing decision support tools. These tools have the potential to
improve care and decrease variation in care delivery [1], and can provide useful diagnostic suggestions
leading to a decrease in diagnostic errors [2]. Probably the most promising approach to improve diagnostic
accuracy is to incorporate decision aids directly into daily clinical practice using computer-assisted
diagnostic support systems [3]. These decision support tools based on expert opinion can provide expert
consultation to physicians [2].
Many clinicians who have to deal with individual patients have a negative attitude towards these systems,
as most are not developed in real-life situations, thus reducing generalisability [1]. Another shortcoming of
currently available tools is that they are mostly based on regression and, hence, are too complex and
time-consuming for use in daily clinical practice [4]. A new way to develop decision support tools is using
data from real-life clinical decisions to develop decision trees.
Decision trees based on real-life data are promising because they can detect previously unknown
interactions between the various items of clinical information and reveal relationships between assessment
outcomes and patient characteristics. Additionally, decision trees are visually easy to interpret and
transparent so that clinicians see the thresholds leading to the outcome. Moreover, they can trace back the
model [5] and they can see what can be expected if the patient’s status changes [6].
We set out to develop a decision tree to predict asthma, chronic obstructive pulmonary disease (COPD)
and asthma–COPD overlap syndrome (ACOS) diagnosis based on careful analysis of 9297 real-life
individual patient assessments in a primary care-based diagnostic support system [7]. All patients were
suspected to have an obstructive pulmonary disease (OPD) and were assessed identically according to a
structured protocol. Each patient was diagnosed by an experienced pulmonologist (n=10). The aim of this
study was to enhance diagnostic accuracy and decrease diagnostic variation. We present a decision tree
that should be able to be implemented as a decision aid in computer-assisted diagnostic support systems
and a simplified and compact version of the decision tree should be able to be used on paper in daily
clinical practice as desk tool.
Method
Study design
We retrospectively analysed data obtained from 2007 until 2012 from the Groningen asthma/COPD
service for primary care (the Netherlands) [7]. The Standards for Reporting Diagnostic Accuracy (STARD)
guidelines were used as a basis for this study. According to Dutch regulations, a separate ethical committee
approval was not required because data were used anonymously and encrypted.
Patient cohort for dataset derivation
We only included patient data from experienced pulmonologists (n=10), who had each assessed ⩾300
patients in the asthma/COPD service, in order to avoid the influence of learning effects in our results.
Patients (aged >15 years) referred to the asthma/COPD service by their general practitioner for diagnostic
assessment were included in the study (table 1). This was an unselected primary care population of
patients with respiratory complaints. The proportion of no-show in the asthma/COPD service is on
average 12%. The initial dataset consisted of 10058 patients. Data from 761 patients were excluded because
they could not perform an assessable spirometry (n=626) or had missing data at random (n=135). The
analysis was therefore based on the remaining 9297 patients.
Predictors
Predictors could be divided into 1) patient characteristics, 2) patient-reported outcomes (PROs) and 3)
spirometry results. All 22 predictors were collected during one regular baseline assessment procedure in
the asthma/COPD service. No adverse effects were to be expected from the assessments.
Patient characteristics
A medical history questionnaire with questions about sex, age, age of onset of respiratory symptoms,
family history, current and past symptoms, exacerbations, allergy and other stimuli provoking symptoms,
current medication, occupation and smoking was collected.
PROs: the Asthma Control Questionnaire and the Clinical COPD Questionnaire
The Asthma Control Questionnaire (ACQ) [8] was used to measure asthma control and contains six
questions. The Clinical COPD Questionnaire (CCQ) [9] was used to measure COPD health status and
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contains 10 questions. In the decision tree analysis we included all individual questions from the ACQ and
CCQ and the total score on each questionnaire, to examine whether disease severity and specific
symptoms could be used to distinguish between the different diagnoses.
Spirometry results
Spirometry was performed according to current guidelines [10, 11]. We analysed post-bronchodilator
(post-BD) forced expiratory volume in 1 s (FEV1), post-BD forced vital capacity (FVC) and post-BD
FEV1/FVC ratio. Also, reversibility of FEV1 (in litres) after 400 μg salbutamol was examined.
Statistical analyses
SPSS package 22.0 (IBM Corp., Armonk, NY, USA) was used for the statistical analyses. Initially,
continuous variables were divided into categorical counterparts using optimal binning [12] to enhance
the performance and accuracy of the decision tree. The number of predefined categorical counterparts
was two, except for the body mass index and FEV1 post-BD, where we chose to accept a maximum of
four counterparts (table 2) [3, 13].
TABLE 1 Overview of the patient characteristics from the derivation and validation databases
Derivation database# Validation database¶
Patients 9297 3142+
Diagnosis
COPD 1716 (18.5) 555 (17.7)
Asthma 4125 (44.4) 685 (21.8)
Probable asthma 836 (26.6)
ACOS 711 (7.6) 247 (7.9)
Other 2745 (29.5) 818 (26.0)
Patient characteristics
Male 4146 (44.6) 1347 (42.9)
Smoked
Never smoked 2833 (30.5) 1182 (37.7)
Ever smoked 6464 (69.5) 1895 (62.3)
Family history
No or unknown family history 4525 (48.7) 2146 (68.3)
Positive family history 4772 (51.3) 996 (31.7)
Allergy
No allergy 5542 (58.9) 932 (29.7)
⩾1 allergy 3755 (39.9) 1651 (52.5)
Missing data 105 (1.1) 559 (17.8)
Hyperreactivity
No hyperreactivity 3105 (33.4) 2347 (74.7)
Hyperreactivity present 6192 (66.6) 795 (25.3)
Occupational risk
No occupational risk 8742 (94.0) Unknown
Occupational risk present 555 (6.0)
Age years 53.3±17.1 49.4±16.8
Age of onset years 35.4±23.3 36.1±21.6
Total ACQ score 1.2±0.9 1.3±0.9
Total CCQ score 1.4±0.9 1.5±0.9
Lung function post bronchodilator
FEV1 L 2.9±1.0 2.9±1.0
FEV1 % predicted 89.4±19.3 92.1±20.0
FVC L 3.9±1.1 4.0±1.1
FVC % predicted 101.6±16.5 106.7±35.9
FEV1/FVC 73.0±12.9 72.1±13.6
Reversibility % 6.1±7.5 6.9±9.0
Data are presented as n, n (%) or mean±SD. COPD: chronic obstructive pulmonary disease; ACOS:
asthma–COPD overlap syndrome; ACQ: Asthma Control Questionnaire; CCQ: Clinical COPD Questionnaire;
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity. #: database from the asthma/COPD
service used for development of the decision tree (Groningen, the Netherlands); ¶: database from the
asthma/COPD service used in the external validation (Rotterdam, the Netherlands); +: total diagnosed was
3141 because one patient could not perform a proper lung function test.
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Development of the decision tree
We used the exhaustive Chi-squared Automatic Interaction Detection (CHAID) method [13] to develop
our decision tree. For an overview of relevant decision tree concepts see figure 1. In the decision tree we
combined “indication of restriction”, “diagnosis unclear” or “no disease” with “other”. The maximum tree
depth was five levels and the significance level for merging nodes was 0.01. Bonferroni correction was
applied to correct for overstating of the significance level caused by multiple comparisons. The minimum
number of patients in a child leaf was 94 (>1% of the total number of patients).
A simplified compact version of the decision tree [13] was developed by reducing the initial decision tree
with a technique called pruning. Branches were pruned if the difference in main category between the
parent leaf and the child leaf was <10%. For example, if the proportion of asthmatics in the parent leaf is
43% and the proportion of asthmatics in the child leaf is 40%, the branch will be pruned because the
difference is <10%. To enhance usability we determined the maximum tree depth to be four levels and
discussed this tool with experienced clinicians.
TABLE 2 Transformation of continuous predictors to ordinal predictors
Predictor Established categories
Patient characteristics
Age years <55
⩾55
Age of onset years <38
⩾38
BMI kg·m−2 <22
⩾22 and <36
⩾36
Allergy total No allergy
⩾1 allergy
Hyperreactivity No hyperreactivity
⩾1 hyperreactivity
ACQ and CCQ
ACQ1 0 or 1
⩾2
ACQ total, ACQ2, ACQ4, ACQ5, ACQ6 0
⩾1
CCQ subscale mental, CCQ1, CCQ2, CCQ4 0
⩾1
CCQ subscale symptoms, CCQ6 0 or 1
⩾2
CCQ7 <6
⩾6
Spirometry results
FEV1 % predicted <78
⩾78 and <92
⩾92 and <102
⩾102
FVC % predicted <81
⩾81
Reversibility % <7
⩾7
Continuous predictors were transformed to ordinal predictors using minimum descriptive length
discretisation. It was not possible to create bins for Asthma Control Questionnaire (ACQ) question 3,
Clinical COPD Questionnaire (CCQ) questions 3, 5, 8, 9 or 10, CCQ total or CCQ subscale functional,
because of low association with the dependent variable. BMI: body mass index; FEV1: forced expiratory
volume in 1 s; FVC: forced vital capacity.
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Internal validation
We validated our decision tree with the “10-fold cross validation” method (figure 2). The dataset was
randomly divided into ten mutually exclusive subsets and each subset was held out in turn to function as
validation sample. The decision tree was then developed on the combined nine remaining subsets. This
procedure was repeated 10 times so that each subset was used once as validation set, according to WITTEN
et al. [14], so that the final decision tree was based on 100 tree analyses.
External validation
We validated our decision tree in an external database of another Dutch asthma/COPD service for
primary care that operates in Rotterdam and has a similar structure to the service in Groningen. Patients
were assessed by two pulmonologists and two specialised general practitioners. This database is called the
validation database.
Results
Patient characteristics
We included 9297 patients (mean age 53±17 years, 44.6% male, diagnosis by pulmonologist: 44.4%
asthma, 18.5% COPD, 7.6% ACOS and 29.5% other). Patients from the validation dataset (n=3142) were
comparable with patients from the derivation dataset (mean age 49±17 years, 42.9% male, 21.8% asthma,
26.6% “probable asthma”, 17.7% COPD, 7.9% ACOS and 26.0% other). However, the proportion of
asthma diagnoses given by the pulmonologists differed (derivation: 44.4% asthma; validation: 21.8%
asthma) (table 1).
Exhaustive CHAID analysis
The final decision tree consisted of the following predictors (in order of importance): FEV1/FVC, age of
onset, smoking, allergy, reversibility, ACQ question 5 (“In general, during the past week, how much of the
time did you wheeze?”), age, FEV1 and bronchial hyperreactivity. Comparisons between the predicted
diagnoses and actual pulmonologists’ diagnoses are given in tables 3–5. The average predictive value of the
decision tree before pruning was 69.0% (proportion correct: asthma 78.9%, COPD 84.7%, ACOS 31.6%
and other 53.9%) (table 3). The most important pathways leading to diagnoses were: 1) no obstruction,
Patients with
respiratory complaints
n=9297
Child leafChild leaf
Child leaf
Predictor X1
Predictor X2
Predictor X3
Predictor X4
Predictor X5
Child leaf
Child leafChild leaf
Child leafChild leaf
End leaf
n >94
End leaf
n >94
Branch
Tree depth = 5 levels
Node
FIGURE 1 The most important decision tree concepts. In our analyses we included 9297 patients. The
minimum accepted number of patients in an end leaf was set at 94, which is >1% of the patient total.
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onset age <38 years, allergy and reversibility ⩾7%, leading to asthma (89% correct); and 2) obstruction,
smoked, onset age ⩾38 years and FEV1 <78% predicted, leading to COPD (81% correct). ACOS was only
predicted by one pathway (obstruction, smoked, onset age <38 years). The pathway “no obstruction, no
allergy, reversibility <7% and onset age ⩾38 years” did not predict diagnosis and led to the category
“other” in 1961 patients, which is 21.2% of the total patient population and is the largest branch. For an
overview of all pathways, see table 6.
The simplified compact version of the decision tree (figure 3) was slightly more efficient, with 11 termination
leaves. The simplified tree is practical in clinical practice. However, the overall precision of this tree was
slightly lower than the complete decision tree: overall 67.5% were correctly predicted (proportion correct:
asthma 72.1%, COPD 77.9%, ACOS 42.5% and other 60.7%). After discussion with experienced clinicians
(n=3), we decided to exclude FEV1 post-BD, to enhance applicability. For a comparison between the
predicted diagnoses from this simplified decision tree and the actual pulmonologists’ diagnoses, see table 4.
Internal validation
The error rates of the 10 repeated decision tree analyses ranged from 0.314 to 0.318, with an average error
of 0.316. Variation in error rates exist because small differences in random splits used for the “10-fold
cross validation” occur. We have selected the decision tree with the lowest error rate (0.314).
External validation
Our decision tree could correctly predict diagnosis in 54.2% of the patients in the validation dataset
(proportion correct: asthma 77.8%, COPD 82.7%, ACOS 23.9% and other 39.4%). In 836 (26.6%) patients
from the validation database with unclear diagnosis, the assessing pulmonologists added a remark in the
database with the notion “probable asthma”. We repeated the validation procedure and included “probable
asthma” patients in the asthma group. The accuracy of our decision tree improved substantially: the overall
proportion correct became 65.1% (ACOS 23.9%, COPD 82.7%, asthma 77.8% and other 50.5%), which is
comparable with the accuracy of the decision tree in the derivation dataset (table 5).
Discussion
Main results
In this study, we have presented a thoroughly developed diagnostic support tool, based on a large database
with real-life primary care patients suspected to have OPD who have received a structured assessment and
1st test
2nd test
3rd test
4th test
5th test
6th test
7th test
8th test
9th test
10th test
Data (n=9297)
Validation
Validation
Validation
Validation
Validation
Validation
Validation
Validation
Validation
Validation
FIGURE 2 Overview of a single “10-fold cross validation”. This was repeated 10 times and each time an error rate
was produced. In this study we used the results of the decision tree with the lowest error rate, which was 0.314.
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an expert diagnosis. We chose this patient population because OPDs like asthma and COPD are common
in primary care, and underdiagnosis of COPD and misdiagnosis between COPD and asthma are an
important clinical problem [15]. Our tool was able to correctly predict diagnosis in 69% of the patients
(proportion correct: asthma 79%, COPD 85% and ACOS 32%) and was based on a combination of patient
characteristics, symptoms and spirometry results, which are part of guideline recommended assessments.
Our decision tree provides a simple, well interpretable and practical overview that generates a diagnostic
suggestion for primary care patients suspected to have an OPD. Additionally, we have developed a
simplified version of the decision tree to be used as a desk tool in clinical practice. This slightly decreased
the accuracy of the original decision tree (proportion correct: overall 68%, asthma 72% and COPD 78%)
but increased the proportion of correctly predicted ACOS patients (43%).
TABLE 4 Comparison of individual patient diagnoses given by the pulmonologists and diagnoses predicted with the simplified
decision tree
Diagnosis by pulmonologist Diagnosis predicted by simplified tree Total Correct
ACOS COPD Asthma Other#
ACOS 302 278 92 39 711 (7.6) 302 (42.5)
COPD 252 1337 61 66 1716 (18.5) 1337 (77.9)
Asthma 183 80 2976 886 4125 (44.4) 2976 (72.1)
Other# 46 110 924 1665 2745 (29.5) 1665 (60.7)
Total 783 (8.4) 1805 (19.4) 4053 (43.6) 2656 (28.6) 9297 (100) 6280 (67.5)
Data are presented as n or n (%). ACOS: asthma–COPD overlap syndrome; COPD: chronic obstructive pulmonary disease. #: “diagnosis
unclear”, “indication of restriction” or “no disease”. Bold indicates diagnoses that were correctly predicted.
TABLE 5 Comparison of individual patient diagnoses given by the pulmonologists from the validation asthma/COPD service
and diagnoses predicted with the decision tree
Diagnosis by validation pulmonologist Diagnosis predicted by decision tree Total Correct
ACOS COPD Asthma Other#
ACOS 59 151 35 2 247 (7.9) 59 (23.9)
COPD 53 459 37 6 555 (17.7) 459 (82.7)
Asthma 42 32 533 78 685 (21.8) 533 (77.8)
Probable asthma 11 7 580 238 836 (26.6) 580 (69.4)
Other# 10 59 336 413 818 (26.0) 413 (50.5)
Total 175 708 1521 737 3141 (100.0) 2044 (65.1)
Data are presented as n or n (%). ACOS: asthma–COPD overlap syndrome; COPD: chronic obstructive pulmonary disease. #: “diagnosis
unclear”, “indication of restriction” or “no disease”. Bold indicates diagnoses that were correctly predicted.
TABLE 3 Comparison of individual patient diagnoses given by the pulmonologists and diagnoses predicted with the decision
tree
Diagnosis by pulmonologist Diagnosis predicted by decision tree Total Correct
ACOS COPD Asthma Other#
ACOS 225 355 98 33 711 (7.6) 225 (31.6)
COPD 135 1454 68 59 1716 (18.5) 1454 (84.7)
Asthma 162 101 3253 609 4125 (44.4) 3253 (78.9)
Other# 28 128 1109 1480 2745 (29.5) 1480 (53.9)
Total 550 (5.9) 2038 (21.9) 4528 (48.7) 2181 (23.5) 9297 (100) 6412 (69.0)
Data are presented as n or n (%). ACOS: asthma–COPD overlap syndrome; COPD: chronic obstructive pulmonary disease. #: “diagnosis
unclear”, “indication of restriction” or “no disease”. Bold indicates diagnoses that were correctly predicted.
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TABLE 6 Branches in the decision tree and an overview of the predicted diagnoses
Rule branch Main outcome Total leaf
n (% total leaf)
ACOS
n (% total)
COPD
n (% total)
Asthma
n (% total)
Other#
n (% total)
FEV1/FVC ⩾70% predicted Asthma 1415 (15.2) 11 (0.8) 3 (0.2) 1108 (78.3) 293 (20.7)
Onset age <38 years
⩾1 allergy
Reversibility <7%
FEV1/FVC ⩾70% predicted Asthma 724 (7.8) 11 (1.5) 1 (0.1) 647 (89.4) 65 (9.0)
Onset age <38 years
⩾1 allergy
Reversibility ⩾7%
FEV1/FVC ⩾70% predicted Asthma 829 (8.9) 16 (1.9) 5 (0.6) 593 (71.5) 215 (25.9)
Onset age <38 years
No allergy
Wheezing
FEV1/FVC ⩾70% predicted Asthma 548 (5.9) 11 (2.0) 7 (1.3) 276 (50.4) 254 (46.4)
Onset age ⩾38 years
⩾1 allergy
Reversibility <7%
FEV1/FVC ⩾70% predicted Asthma 181 (1.9) 8 (4.4) 2 (1.1) 133 (73.5) 38 (21.0)
Onset age ⩾38 years
⩾1 allergy
Reversibility ⩾7%
FEV1/FVC <70% predicted Asthma 356 (3.8) 35 (9.8) 43 (12.2) 219 (61.5) 59 (16.6)
Never smoked
FEV1/FVC <70% predicted ACOS 783 (8.4) 302 (38.6) 252 (32.2) 183 (23.4) 46 (5.9)
Onset age <38 years
Smoked
FEV1/FVC <70% predicted COPD 1142 (12.3) 164 (14.4) 928 (81.3) 19 (1.7) 31 (2.7)
Onset age ⩾38 years
Smoked
FEV1 <78% predicted
FEV1/FVC <70% predicted COPD 257 (2.8) 26 (10.1) 203 (79.0) 11 (4.3) 17 (6.6)
Onset age ⩾38 years
Smoked
FEV1 ⩾78% and <92% predicted
Reversibility <7%
FEV1/FVC <70% predicted COPD 168 (1.8) 56 (33.3) 79 (47.0) 18 (10.7) 15 (8.9)
Onset age ⩾38 years
Smoked
FEV1 ⩾78% and <92% predicted
Reversibility ⩾7%
FEV1/FVC <70% predicted COPD 238 (2.6) 32 (13.4) 127 (53.4) 32 (13.4) 47 (19.7)
Onset age ⩾38 years
Smoked
FEV1 ⩾92% predicted
FEV1/FVC ⩾70% predicted Other# 1961 (21.2) 33 (1.7) 61 (3.1) 561 (28.6) 1306 (66.6)
Onset age ⩾38 years
No allergy
FEV1/FVC ⩾70% predicted Other# 695 (7.5) 6 (0.9) 5 (0.7) 323 (46.8) 359 (51.7)
Onset age <38 years
No allergy
No wheezing
ACOS: asthma–COPD overlap syndrome; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity. #: “diagnosis unclear”, “indication of restriction” or “no disease”. Bold indicates diagnoses that were correctly predicted. Spirometry
results were taken after admission of bronchodilation.
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Limitations
Although most patients could be correctly diagnosed with our decision tree, still 31% of the patients could
not be diagnosed correctly using the diagnosis originally made by the pulmonologist as gold standard.
This might have been caused by the diagnostic variation among pulmonologists, which was previously
described by METTING et al. [7]. Despite this diagnostic variation between the pulmonologists, additional
data from 1856 patients showed that most diagnoses were confirmed at follow-up (confirmed in 92% of
the asthma patients, in 86% of the COPD patients and in 73% of the ACOS patients). According to
BUFFELS et al. [16], in the absence of a gold standard, a pulmonologist’s diagnosis is most accurate. Of
course, elimination of all uncertainty in a diagnostic support tool is not feasible; this would cost too much
in terms of resources [3]. Response to treatment might determine whether the predicted diagnosis was
satisfactory [17] and the predicted diagnosis can be considered as a working diagnosis.
No allergy
Never smoked
Unclear
Allergy
Onset ≥38 years
Smoked
Onset <38 years
Obstruction
77% asthma
74% COPD
74% asthma
72% asthma
89% asthma
78% asthma
Unclear
Unclear
39% ACOS
UnclearNo allergy
Allergy
No allergy
Allergy
Primary
care adult
patient 
with 
respiratory 
complaints
No obstruction
Onset ≥38 years
Onset <38 years
Reversibility ≥7% 
Reversibility <7% 
Reversibility <7% 
No wheezing
Wheezing
Reversibility ≥7%
FIGURE 3 The simplified decision tree derived from the total decision tree gives an overview of the important
pathways. COPD: chronic obstructive pulmonary disease; ACOS: asthma–COPD overlap syndrome.
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Another limitation is that the decision tree does not differentiate between patients with or without disease.
The diagnosis “no disease” is combined with “indication of restriction” and “diagnosis unclear” in the
umbrella term “other”. However, the proportion of patients without disease was very small (n=709, 7.6%)
and would therefore be difficult to predict with a decision tree.
Finally, the decision tree has a low accuracy in diagnosing ACOS. Again, using the diagnosis originally
made by the pulmonologist as gold standard, it means that the pulmonologists had little agreement about
this diagnosis at the time the data were collected. It is known that ACOS is difficult to diagnose from both
asthma and COPD, which was reflected in our decision tree. Differentiating between asthma, COPD and
ACOS is important because the treatment and prognosis are different [15]. ACOS patients have more
respiratory symptoms, more functional limitations, and are more frequently hospitalised [18]. In 2014, the
Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Global Initiative for Asthma
(GINA) presented new guidelines for ACOS that might enhance future diagnostic accuracy [19] and will
probably lead to more consensus among physicians.
Strengths and weaknesses
Internal validity
CHAID is based on the maximum likelihood ratio and is considered to be at least as good as log
regression techniques; however, it is easier to interpret and no calculation of risk scores is needed because
the user can simply follow the tree [20]. The exhaustive CHAID method provides an even more thorough
heuristic for finding the optimal way of grouping the categories of each predictor, and provides a better
suited approximation for the Bonferroni correction [13]. We performed the “10-fold cross validation”
method because this method is considered to be the best validation method [14].
We used specialists’ diagnoses, which we considered to be the gold standard. Patients in the asthma/COPD
service were diagnosed from spirometry and history data through the Internet. Previously, LUCAS et al. [21]
showed that pulmonologists can reliably diagnose patients from written spirometry and history data.
However, all diagnoses in this system were based on the available variables and were not confirmed by, for
example, bronchial hyperresponsiveness testing, exhaled nitric oxide fraction or extended radiology,
because these are not used in primary care practice. One can therefore argue that these diagnoses are not
fully confirmed and are just a step in the diagnostic process.
External validation
The decision tree could correctly predict 54% of the patients in the validation dataset. However, adding
“probable asthma” to the asthma group improved the accuracy substantially (from 54% to 65%). The lower
overall prediction performance in the validation dataset might be caused by the difference in opinion from
the pulmonologists who assessed the patients in the validation dataset to the pulmonologists in the
original dataset. We make this assumption because the proportion of patients diagnosed with asthma
by the pulmonologists was lower (22% in the validation dataset, compared with 44% in the original
dataset). Most patients with “probable asthma” in Rotterdam were referred for a histamine provocation test
(n=628, 75%). Apparently, pulmonologists from the derivation asthma/COPD service in Groningen
establish the diagnosis of asthma more quickly than the pulmonologists in the validation asthma/COPD
service. Additional analyses showed that probable asthma patients had on average lower reversibility
compared with asthma patients (mean±SD reversibility: probable asthma patients 3.6±4.9%, asthma
patients 12.5±12.1%; p<0.001).
An effectiveness study has shown that patients who were diagnosed and followed-up by the asthma/COPD
service in Groningen improved in health status, asthma control and exacerbation rate [7]. We therefore
assume that our decision tree is of added value for primary care respiratory patients and that the external
validity of our decision tree is high because we have included a large sample of real-life primary care
patients, while our decision tree is developed with common predictors that are part of guideline
recommended assessments in patients suspected to have an OPD [10, 11]. Therefore, the generalisability of
our decision tree is expected to be high.
Comparison with existing literature
In the field of respiratory medicine, several decision trees have been developed to predict severity [6],
mortality [22], hospitalisation [4] and clinical outcomes [23]. In this article, we have presented the first
real-life decision tree to predict diagnosis in patients suspected to have an OPD in primary care daily
clinical practice. This is important because diagnostic errors are common [3, 24, 25] in general practice
[26]. 10–15% of all diagnoses are estimated to be incorrect [26]. These errors affect patients outcomes [24,
27], and can lead to inappropriate patient care and increased healthcare costs [2, 3]. Being a physician can
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be demanding [25] and making decisions under time pressure can negatively influence diagnostic
performance [17].
In the past 20 years, a consensus has been reached about a dual-system theory that proposes two modes of
clinical decision making. The first system consists of one nonverbal intuitive cognition system, which is
fast but error prone [17] and is based on intuitive reasoning, while the second system is based on the
classical analytical reasoning approach [26]. Experienced physicians use both systems while novices mostly
rely on the second hypothesis-testing system [17]. The decision support tool presented here matches both
pathways by providing diagnostic suggestions. It points out possible diagnoses along with an estimation of
probability, which can support the nonverbal intuitive cognition system. It also supports the analytic
reasoning approach by giving feedback so that the initial diagnosis can be confirmed or dismissed. Our
decision tree can be used by novices and experienced physicians, so that novices can function like a more
experienced physician [1, 24] and experts can use the tree as a feedback tool to confirm their initial
diagnosis or suggest another.
Spirometry is considered to be essential for proper diagnosis, according to the GOLD and GINA
guidelines [18]. Symptom-based questionnaires in combination with spirometry enhance diagnostic
accuracy of OPD even more [15]. Our decision tree combined both and produced transparent thresholds
for continuous variables like age or reversibility that can be used in clinical practice.
In the past years, more emphasis has been given to personalised medicine instead of the “one size fits all”
approach. We found that there are different pathways leading to the same diagnosis. We found six
pathways leading to asthma and four leading to COPD (table 6). This is consistent with the new insights
that asthma and COPD are heterogeneous diseases.
Implementation
We have presented a computer-assisted diagnostic support system for OPDs based on real-life primary
care data that can be implemented in digital automated decision-making programmes. The transparency of
our decision tree is valuable because the proposed diagnosis is accompanied by a probability that can
support the physicians in diagnosing and treating their individual patients. This might enhance diagnostic
accuracy. The simplified and compact paper version of the decision tree could be helpful in clinical
practice as a desk tool.
Recommendation for future research
The next step is to validate our decision tree in other primary care populations and in clinical practice, to
optimise the predictive value and the applicability in individual patients with suspicion of OPD.
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